ENTERA BIO IS-0000769 (5DT) - Net Assets
Based on the latest financial reports, ENTERA BIO IS-0000769 (5DT) has net assets worth €13.10 Million EUR (≈ $15.32 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€15.99 Million ≈ $18.70 Million USD) and total liabilities (€2.89 Million ≈ $3.38 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore 5DT total assets for the complete picture of this company's asset base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €13.10 Million |
| % of Total Assets | 81.92% |
| Annual Growth Rate | -12.71% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 40.89 |
ENTERA BIO IS-0000769 - Net Assets Trend (2021–2025)
This chart illustrates how ENTERA BIO IS-0000769's net assets have evolved over time, based on quarterly financial data. Check ENTERA BIO IS-0000769 (5DT) tangible equity ratio to evaluate the tangible quality of the company's equity base.
Annual Net Assets for ENTERA BIO IS-0000769 (2021–2025)
The table below shows the annual net assets of ENTERA BIO IS-0000769 from 2021 to 2025. For live valuation and market cap data, see 5DT stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €13.10 Million ≈ $15.32 Million |
+62.14% |
| 2024-12-31 | €8.08 Million ≈ $9.45 Million |
-22.20% |
| 2023-12-31 | €10.39 Million ≈ $12.14 Million |
-11.64% |
| 2022-12-31 | €11.75 Million ≈ $13.74 Million |
-47.91% |
| 2021-12-31 | €22.57 Million ≈ $26.38 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to ENTERA BIO IS-0000769's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 4294000000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €138.47 Million | 1056.92% |
| Total Equity | €13.10 Million | 100.00% |
ENTERA BIO IS-0000769 Competitors by Market Cap
The table below lists competitors of ENTERA BIO IS-0000769 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Alithya Group Inc
NASDAQ:ALYAF
|
$61.60 Million |
|
Ipopema Securities SA
WAR:IPE
|
$61.63 Million |
|
Glomac Bhd
KLSE:5020
|
$61.66 Million |
|
China Tianrui Group Cement Company Limited
F:T18
|
$61.67 Million |
|
NTT System SA
WAR:NTT
|
$61.52 Million |
|
Lumos Diagnostics Holdings Ltd
AU:LDX
|
$61.45 Million |
|
Lion Finance Group PLC
LSE:BGEO
|
$61.44 Million |
|
PP Properti Tbk PT
JK:PPRO
|
$61.44 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ENTERA BIO IS-0000769's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 8,080,000 to 13,101,000, a change of 5,021,000 (62.1%).
- Net loss of 11,439,000 reduced equity.
- New share issuances of 13,444,000 increased equity.
- Other factors increased equity by 3,016,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-11.44 Million | -87.31% |
| Share Issuances | €13.44 Million | +102.62% |
| Other Changes | €3.02 Million | +23.02% |
| Total Change | €- | 62.14% |
Book Value vs Market Value Analysis
This analysis compares ENTERA BIO IS-0000769's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 6.17x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 2.23x to 6.17x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €0.78 | €1.75 | x |
| 2022-12-31 | €0.41 | €1.75 | x |
| 2023-12-31 | €0.29 | €1.75 | x |
| 2024-12-31 | €0.21 | €1.75 | x |
| 2025-12-31 | €0.28 | €1.75 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently ENTERA BIO IS-0000769 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -87.31%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -27235.71%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.22x
- Recent ROE (-87.31%) is above the historical average (-91.24%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -54.01% | -2134.33% | 0.02x | 1.15x | €-14.44 Million |
| 2022 | -111.20% | -9754.48% | 0.01x | 1.12x | €-14.25 Million |
| 2023 | -85.59% | 0.00% | 0.00x | 1.13x | €-9.93 Million |
| 2024 | -118.08% | -5271.27% | 0.02x | 1.16x | €-10.35 Million |
| 2025 | -87.31% | -27235.71% | 0.00x | 1.22x | €-12.75 Million |
Industry Comparison
This section compares ENTERA BIO IS-0000769's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $2,058,506,458
- Average return on equity (ROE) among peers: -59.27%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ENTERA BIO IS-0000769 (5DT) | €13.10 Million | -54.01% | 0.22x | $61.53 Million |
| PROQR THERAPEUTICS EO-04 (0PQ) | $49.37 Million | -85.44% | 1.28x | $142.34 Million |
| TIZIANA LIFE SCIENCES LTD (0RP) | $19.57 Million | -78.67% | 0.35x | $141.34 Million |
| Theravance Biopharma Inc (0TB) | $243.06 Million | -74.97% | 0.23x | $828.57 Million |
| I-MAB SPONS.ADS/1 -0001 (0VY) | $230.94 Million | -20.03% | 0.13x | $212.27 Million |
| PreveCeutical Medical Inc (18H) | $-4.64 Million | 0.00% | 0.00x | $3.34 Million |
| Argen-X (1AE) | $7.32 Billion | 17.64% | 0.19x | $41.67 Billion |
| WAVE LIFE SCIENCES LTD. (1U5) | $32.50 Million | -376.16% | 5.37x | $1.07 Billion |
| BIOCURE TECHNOLOGY INC. (1WH) | $1.34 Million | -19.58% | 0.49x | $960.84K |
| ZAI LAB LTD0000006 (1ZLB) | $796.12 Million | -42.03% | 0.30x | $1.82 Billion |
| BioNTech SE (22UA) | $11.89 Billion | 86.54% | 0.33x | $20.05 Billion |
About ENTERA BIO IS-0000769
Entera Bio Ltd., a clinical stage company, engages in the development of oral peptides and protein replacement therapies in Israel and internationally. It develops EB613, an oral teriparatide, which completed the Phase II clinical trial for the treatment of osteoporosis and Phase I clinical trial for the treatment of stress fractures. The company is also involved in the development of EB612, a ta… Read more